期刊文献+

卫喜康改善膀胱灌注后药物保留时间过短的可行性研究

The research of the feasibility of improving too short drug retention time after bladder perfusion with Vesicare
原文传递
导出
摘要 目的探讨卫喜康改善膀胱灌注后药物保留时间过短的可行性。方法对44例膀胱肿瘤电切术后行膀胱灌注,发生尿频尿急等,药物保留困难,药物明显外漏,在常规处理基础上,药物保留时间仍不到15分钟的病例,口服卫喜康一周,再次灌注,比较小便次数、尿急、尿失禁、保留时间及满意度情况。结果患者治疗前后膀胱灌注OABSS评分、保留时间、满意度等方面,差别均有统计学意义(均P<0.01)。结论对膀胱肿瘤术后膀胱灌注药物保留时间过短的患者,在常规处理效果不佳的情况下,口服卫喜康可以改善大部分患者的尿频尿急,增加膀胱灌注药物保留时间,提高疗效及满意度。 Objective Try to research the feasibility of Vesicare which improving too short drug retention time after bladder chemotherapy drugs perfusion.Methods Include 44 cases postoperative bladder tumor patients who can't tolerate procedure of bladder perfusion and liquid retention time less than 15 minutes after routing treatment.These patients take oral Vesicare one week before next bladder perfusion.Compare their OABSS,times of drug retention,satisfaction degree recorded after with before get oral drugs.Results There are statistic differences in OABSS,retention time of bladder perfusion,satisfaction degree after take oral drugs(P〈0.05).Conclusion If it is too short about drug retention of postoperative bladder perfusion patients' time,Vesicare for one week before next procedure should improve the retention time of most patients;also get better effect and satisfaction,in the case of no expected effect by regular treatment.
出处 《首都食品与医药》 2016年第24期69-70,共2页 Capital Food Medicine
关键词 膀胱肿瘤 膀胱灌注 药物保留时间 卫喜康 Bladder tumor Bladder perfusion Drug retention time Vesicar
  • 相关文献

参考文献3

二级参考文献23

  • 1丁影.膀胱癌术后行膀胱灌注化疗的临床护理[J].中国药物经济学,2012,22(06):355-356.
  • 2Nowara A,Witek A,Wilk K. Diagnostic and treatment of overactivebladder[J].{H}Ginekologia polska,2007,(07):549-553.
  • 3Nelson CP,Gupta P,Napier CM. Functional selec-tivity of muscarinic receptor antagonists for inhibition of M 3-mediated phosphoinositide responses in guinea pig urina-ry bladder and submandibular salivary gland[J].J Phar-macol Exp Ther,2004.1255-1265.
  • 4Abrams P,Andersson KE. Muscarinic receptor antagonists for overactive bladder[J].{H}BJU International,2007,(05):987-1006.
  • 5Sussman DO. Overative bladder:treatment options in pri-mary care medicine[J].{H}Journal of the American Osteopathic Association,2007,(09):379-385.
  • 6Uchida S,Kagitani F,Hotta H. Mechanism of the reflex inhibition of heart rate elicited by acupuncture-like stimu-lation in anesthetized rats[J].{H}Autonomic Neuroscience:Basic & Clinical,2008,(1-2):12.
  • 7Saika T,Tsushima T,Nasu Y. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer:a prospective,randomized controlled study[J].{H}WORLD Journal OF UROLOGY,2010,(04):413-418.
  • 8那彦群;叶章群;孙光.中国泌尿外科疾病诊断治疗指南手册(2011版)[M]{H}北京:人民卫生出版社,201128.
  • 9陈孝平.8年制规划教材外科学[M]{H}北京:人民卫生出版社,2010849.
  • 10Witjes JA. Topic issue on new treatments in bladder cancer[J].{H}WORLD Journal OF UROLOGY,2009,(03):285-287.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部